Eurobio-Scientific SA ALERS

RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2026 Revenue up 4.5% to 84.5 M€ Proprietary products account for 37% of revenue46% of revenue generated outside France Free cash flow of €4 million after investmentsNet debt of €147.4 million, including the EB Development shareholder loanAcquisition of CareDx’s Lab Solutions business finalized on June 30, 2026 Paris, September 24, 2026 – 17h40 - Eurobio Scientific (FR0013240934, ALERS), a leading French group in in vitro medical diagnostics and life

FIRST HALF OF 2026, CONTINUATION OF THE STRATEGIC TRANSFORMATION First-half revenue up 5% to €84.5 millionContinuation of the Group’s strategy: Proprietary products: 37% of revenueInternational expansion: 47% of revenue generated outside France Paris, July 28, 2026 – 5:45 pm Eurobio Scientific (FR0013240934, ALERS), a leading French group in in vitro medical diagnostics and life sciences, today reports its half-year revenue as of June 30, 2026. 5% revenue growthAs of June 30, 2026, Eurobio Scien

EUROBIO SCIENTIFIC FINALIZES THE ACQUISITION OF CAREDX’s TRANSPLANT LAB PRODUCT DIVISION Acceleration of Eurobio’s strategic plan to become an in-vitro molecular diagnostics (“IVD”) leaderCreation of a global leading provider of kits for genomic typing and transplantation diagnosticsAcquisition of a 100% proprietary products portfolioDeeper capabilities and larger scale with technological and commercial complementarities Paris, July 1st, 2026 ,8 AM CET Eurobio Scientific (FR0013240934, ALERS, PE

BRISBANE, Calif., June 30, 2026--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the closing of the previously announced sale of its Lab Products business to Eurobio Scientific. The transaction closed on June 30, 2026 following receipt of required Swedish regulatory clearance.

2025 ANNUAL RESULTS Annual revenue up 9% to €168 millionRoll-out of the Group’s strategy: Sales of proprietary products up 20%, accounting for 35% of revenueInternationalisation: 42% of revenue generated outside France Continued implementation of the Group’s strategic plan Paris, April 10, 2026 – 5:45 pm Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), ), a leading French group in in vitro medical diagnostics and life sciences, today presents its consolidated annual results for 2025,